Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACQUIVAS
2017-003563-36Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2018
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Response to conjugated pneumococcal vaccine. Status: unknown.
02
Drugs
pneumococcal conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on 2017-003563-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003563-36.